Olivia Esposito • February 5, 2024
Yale New Haven Hospital Heart and Vascular Center – New Haven, CT

Yale New Haven Hospital Heart and Vascular Center offer multidisciplinary services from the latest imaging techniques and genetic profiling of HCM to advanced diagnostic testing, treatment options, and clinical trials – all with an emphasis on compassion and communication.

Yale New Haven’s well-established HCM center provides specialized, expert physicians and staff specially trained to manage HCM. This multidisciplinary team has the experience necessary to provide seamless care to patients and their families at every age and stage of this disease. Yale has three Co-Directors of the HCM Program: Dr. Rachel Lampert, Dr. John Stendahl, and Dr. Sounok Sen.

The HCM team includes specialists in:

  • Adult and Pediatric Cardiology
  • Advanced Heart Failure Cardiology
  • CardiacaAesthesia
  • Cardiac Electrophysiology
  • Cardiac Genetics
  • Cardiac Imaging
  • Cardiac Surgery
  • Cardio-Obstetrics
  • Interventional Cardiology
  • Nutrition
  • Research
  • Social Work

Services include medical management, genetic counseling, family screening, advanced management of heart rhythm disorders, catheter-based procedures, and surgical interventions when necessary. Yale New Haven HCM Team provides clinical trial access and monthly support group meetings.

The Yale New Haven HCM Team recently participated in our BigHearted Warriors Unite Webinar Series. If you would like to watch team members Dr. Rachel Lampert, Dr. John Stendahl,  Dr. Sounok Sen, Dr.Arya Mani, and Dr. Nikhil Sikand’s free Bighearted Warriors education webinar, please visit  https://www.youtube.com/live/xXvmdTJNxKQ?si=oFRIw70lYUmM-FL6.

For more information on the Yale New Haven HCM Program in New Haven, CT, please visit:  https://4hcm.org/yale/


For more information on all HCMA-recognized centers of excellence, please visit  https://4hcm.org/center-of-excellence/.

HCMA Blog

Medical Management May

April 30, 2025
Medical Management means using medicines and other non-invasive therapies to relieve symptoms. It's exciting that new treatments for HCM are being studied and that the FDA approved Camzyos in 2022! HCM can cause various symptoms depending on how stiff the heart is, how much scarring (fibrosis) there is, and whether there is obstruction. Some people have no noticeable symptoms. Common symptoms are chest pain/pressure, shortness of breath, lightheadedness, fatigue, palpitations, and brain fog. Syncope (fainting) is dramatic but not as common as the other symptoms. Medications are the first-line treatment for symptoms of HCM. If patients can't take one class of medication, they can try a medication from a different class. Here are some medications used to treat HCM and what they're for: Beta Blockers - make your heart beat slower and relax better. They allow the heart to fill more completely between beats. They can lower blood pressure and relieve symptoms. Calcium Channel Blockers - used to lower blood pressure and slow the heart rate. May reduce symptoms from obstruction in HCM. Myosin Inhibitors - cause the heart to beat with less force. They may reduce obstruction and septal thickness in some patients. Camzyos (mavacamten) is the first of this class of medication. For more information, click HERE . Antiarrhythmics - help to restore normal rhythm in the heart. Blood Thinners - anticoagulants and anti-platelets make it harder for blood to clot. They are prescribed to reduce the risk of stroke. This risk is higher in patients with afib, aflutter, and artificial heart valves. Diuretics , or "water pills," help the kidneys get rid of extra water and salt, reducing swelling in the body. Sodium Channel Blockers - may reduce gradient in obstructive HCM and can treat chest pain. Some also act as antiarrhythmics. Antibiotics - treat or prevent bacterial infections. In HCM, they may be given before dental work to prevent infective endocarditis. To learn more and see the side effects of these medications, click HERE .
On a green background, a line drawing of a head that has complicated arrows pointing outwards

Decisions in HCM: Why are they so hard?

By Gordon Fox • April 25, 2025
Part 2 of a series on making decisions in HCM. A key reason is that decision making is so difficult is that most decisions involve more than one risk.
Hypertrophic Obsctructive Cardiomyopathy

Camzyos® receives manufacturing and marketing approval for HOCM in Japan

By Erica Friedman • April 22, 2025
Bristol Myers Squibb announces that Camzyos has been approved for Obstructive Hypertrophic Cardiomyopathy in Japan.
More Posts